Gapping up
In reaction to strong earnings/guidance:
- DAN +7.6%, HSBC +6.2%, ON +6.1%, YNDX +6%, BLMN +1.2%, CTB +0.6%
M&A news:
- RHT +51.5% (to be acquired by IBM (IBM) for $190.00/share in cash)
Select Brazil related names showing strength:
- GGB +10.7%, PBR +8.4%, ITUB +6.7%, CIG +5.2%, VALE +4.1%, ABEV +3.6%
Select metals/mining stocks trading higher:
- MT +4%, BBL +2.7%, RIO +2.6%, FCX +2.5%, BHP +2.4%, HMY +1.5%, .
Select tech related names showing strength/rebounding:
- HDP +6% (also may be in response to RHT news) SPLK +4.5% (also may be in response to RHT news) AMD +3.2%, DATA +3%, MU +2.4%, CRM +2.3%, FB +2.2%, NFLX +2%, AMZN +1.5%, MSFT +1.4%, BABA +1.1%,
Other news:
- DRNA +36.5% (Dicerna Pharmaceuticals & Eli Lilly (LLY) enter global licensing and research collaboration -- Dicerna to receive upfront payment of $100 mln and equity investment of $100 mln)
- INNT +10.1% (announces positive effect of larazotide acetate on reducing intestinal permeability in NASH preclinical study)
- GRFS +8.7% (presents AMBAR (Alzheimer Management by Albumin Replacement) top line results)
- ESPR +7.4% (announces 'positive' top-line results from its global, pivotal Phase 3 clinical study of bempedoic acid)
- TXMD +7.1% (FDA approval of TX-001HR: BIJUVA capsules for the treatment of moderate to severe vasomotor symptoms due to menopause)
- TOO +6.1% (reaches settlement agreement with Petróleo Brasileiro S.A. (PBR) with respect to various disputes relating to the previously-terminated charter contracts of the HiLoad DP unit and Arendal Spirit unit for maintenance and safety)
- GSK +3.8% (announces positive phase 3 results for daprodustat in patients with anaemia associated with chronic kidney disease)
- RGNX +3.8% (reports additional positive interim Phase I Trial update for RGX-314)
- CGC +2.6% (issued 43,517 common in the Corporation to acquire certain brand licensing rights for product formats anticipated to be included in the next wave of legal regulated cannabis products for human and animal consumption)
- LCI +2.3% (provides Cody API business sale update; expects impairment charge of $27-33 mln)
- AKRX +2.1% (received a new ANDA approval from the FDA for Clobetasol Propionate Lotion)
- NVS +2% (Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD)
- AMGN +1.8% (reports new FOURIER analysis showing benefit with Repatha)
Analyst comments:
- F +4.3% (upgraded to Buy from Neutral at Goldman)
- MRTX +3.9% (upgraded to Buy from Neutral at Guggenheim)
- PFPT +2.9% (upgraded to Buy from Neutral at Goldman)
- LEN +2.6% (upgraded to Outperform from Neutral at Wedbush)
- ECHO +2.2% (upgraded to Buy from Hold at Loop Capital)
- CERN +1.8% (upgraded to Outperform from Mkt Perform at Leerink Partners)
- AAPL +1.5% (initiated with a Buy at Jefferies)
- NOV +1.2% (upgraded to Outperform from In-line at Evercore ISI)
- COP +1% (upgraded to Buy from Neutral at BofA/Merrill)
![]()